NewYorkBIO’s Holiday Reception is an annual networking event at the iconic New York Stock Exchange building at the heart of New York’s Financial District bringing together members, emerging biotech and life sciences companies developing novel therapeutics with New York’s financial, venture capital, and institutional investment communities.

The FDA granted accelerated approval on Aug. 13 to Bristol Myers Squibb’s Zenbexus (iberdomide), used with Darzalex and dexamethasone, for adults with multiple myeloma who have had at least one prior line of therapy. It is the first approval in the CELMoD class — oral agents that recruit the cell’s own disposal machinery to degrade…

FuzeHub, in partnership with Empire State Development’s NYSTAR division, announced the 2026 winners of the Jeff Lawrence Innovation Fund, awarding $650,000 total ($65,000 each) to 10 collaborative projects pairing New York nonprofits or universities with manufacturing/tech companies across the state. This was a record year with 59 applications received. Several winners are directly relevant to…